KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for West Pharmaceutical Services (WST) over the last 15 years, with Q4 2025 value amounting to $6.7 million.

  • West Pharmaceutical Services' Share-based Compensation rose 5581.4% to $6.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.8 million, marking a year-over-year increase of 2727.27%. This contributed to the annual value of $23.8 million for FY2025, which is 2727.27% up from last year.
  • Per West Pharmaceutical Services' latest filing, its Share-based Compensation stood at $6.7 million for Q4 2025, which was up 5581.4% from $8.4 million recorded in Q3 2025.
  • West Pharmaceutical Services' 5-year Share-based Compensation high stood at $11.3 million for Q3 2021, and its period low was $1.3 million during Q1 2025.
  • Its 5-year average for Share-based Compensation is $6.4 million, with a median of $5.9 million in 2021.
  • In the last 5 years, West Pharmaceutical Services' Share-based Compensation tumbled by 7910.45% in 2023 and then surged by 20714.29% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Share-based Compensation (Quarter) stood at $10.0 million in 2021, then tumbled by 33.0% to $6.7 million in 2022, then crashed by 79.1% to $1.4 million in 2023, then skyrocketed by 207.14% to $4.3 million in 2024, then surged by 55.81% to $6.7 million in 2025.
  • Its Share-based Compensation stands at $6.7 million for Q4 2025, versus $8.4 million for Q3 2025 and $7.4 million for Q2 2025.